Xospata (Gilteritinib) for Acute Myeloid LeukemiaDecember 4, 2018
Xospata (gilteritinib; formerly ASP2215) is an oral FLT3 inhibitor indicated for the treatment of relapsed/refractory acute myeloid leukemia (AML) with an FLT3 mutation. Gilteritinib inhibits AXL, an oncogenic tyrosine kinase that is frequently overexpressed in AML; AXL facilitates FLT3 activation and has been implicated in FLT3 inhibitor resistance. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3 and AXL, as well as anaplastic lymphoma kinase (ALK). This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduction of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.
If you have a Hayes login, click here to view the full report on the Knowledge Center.